Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?

Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows on popular television channels we’re all exposed to.  With the pharma giant recently reporting its Q4 2024 earnings on February 4, 2025, investors certainly have a lot to digest. A number of analysts had suggested Merck could be among the companies with …